Navamedic ASA (OSL:NAVA)

Market Cap	537.18M +24.1%
Revenue (ttm)	539.42M +2.6%
Net Income	-37.89M
EPS	n/a
Shares Out	23.98M
PE Ratio	n/a
Forward PE	142.22
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,529
Average Volume	9,547
Open	22.40
Previous Close	22.40
Day's Range	22.10 - 22.40
52-Week Range	17.10 - 27.90
Beta	0.24
RSI	50.62
Earnings Date	Feb 12, 2026

About Navamedic ASA

Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Norway, Sweden, Denmark, Finland, the Netherlands, and internationally. The company’s product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic and propioni...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 2002
• Employees: 42
• Stock Exchange: Oslo Børs
• Ticker Symbol: NAVA

Financial Performance

In 2024, Navamedic ASA's revenue was 531.44 million, an increase of 3.80% compared to the previous year's 512.00 million. Losses were -5.49 million, -59.92% less than in 2023.